Tanzania - engelsk - Tanzania Medicinces & Medical Devices Authority

astrazeneca united kingdom limited, united kingdom - lisinopril , hydrochlorohiazide - tablets - 20mg + 12.5mg

Tanzania - engelsk - Tanzania Medicinces & Medical Devices Authority

astrazeneca united kingdom limited, united kingdom - lisinopril - tablet, film-coated - 10mg

Tanzania - engelsk - Tanzania Medicinces & Medical Devices Authority

astrazeneca united kingdom limited, united kingdom - lisinopril - tablets - 20mg

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 190mg;   - modified release tablet - 190 mg - active: metoprolol succinate 190mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose light liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 47.5mg;   - modified release tablet - 47.5 mg - active: metoprolol succinate 47.5mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose light liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 95mg;   - modified release tablet - 95 mg - active: metoprolol succinate 95mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose light liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 23.75mg;   - modified release tablet - 23.75 mg - active: metoprolol succinate 23.75mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol tartrate 1 mg/ml;   - solution for injection - 1 mg/ml - active: metoprolol tartrate 1 mg/ml   excipient: sodium chloride water for injection - betaloc iv is indicated for the following indications: · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · suspected or definite myocardial infarction.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

astrazeneca limited - metformin hydrochloride 1000mg;  ; saxagliptin 2.5mg (as saxagliptin hydrochloride) - modified release tablet - 2.5mg/1000mg - active: metformin hydrochloride 1000mg   saxagliptin 2.5mg (as saxagliptin hydrochloride) excipient: carmellose sodium hydrochloric acid   hypromellose magnesium stearate opacode blue s-1-10619 opadry ii yellow 85f92209 opadry white 85f18422 purified water     - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

astrazeneca limited - metformin hydrochloride 1000mg;  ; saxagliptin 5mg (as saxagliptin hydrochloride) - modified release tablet - 5mg/1000mg - active: metformin hydrochloride 1000mg   saxagliptin 5mg (as saxagliptin hydrochloride) excipient: carmellose sodium hydrochloric acid hypromellose magnesium stearate opacode blue s-1-10619 opadry pink 85f14452 opadry white 85f18422 purified water     - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.